Journal of the American College of Cardiology
Volume 38, Issue 3 , Pages 642-644, September 2001

Arteriotomy closure devices—the FDA perspective∗

  • Dale Tavris, MD, MPH

      Affiliations

    • Division of Postmarket Surveillance Office of Surveillance and Biometrics, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland, USA
    • Corresponding Author InformationReprint requests and correspondence: Dr. Dale Tavris, Food and Drug Administration, Division of Postmarket Surveillance, Office of Surveillance and Biometrics, 1350 Piccard Drive, HFZ-451, Rockville, Maryland 20850
    • ,
  • Tom Gross, MD, MPH

      Affiliations

    • Division of Postmarket Surveillance Office of Surveillance and Biometrics, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland, USA
    • ,
  • Beverly Gallauresi, RN, MPH

      Affiliations

    • Division of Postmarket Surveillance Office of Surveillance and Biometrics, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland, USA
    • ,
  • Larry Kessler, ScD

      Affiliations

    • Division of Postmarket Surveillance Office of Surveillance and Biometrics, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland, USA

No abstract is available. To read the body of this article, please view the Full Text online.

 
  • ∗ Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

PII: S0735-1097(01)01453-X

doi:10.1016/S0735-1097(01)01453-X

Journal of the American College of Cardiology
Volume 38, Issue 3 , Pages 642-644, September 2001

Article Tools